Profile data is unavailable for this security.
About the company
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
- Revenue in USD (TTM)8.69m
- Net income in USD-95.53m
- Incorporated2004
- Employees55.00
- LocationCara Therapeutics Inc400 Atlantic Street, Suite 500STAMFORD 06901United StatesUSA
- Phone+1 (203) 406-3700
- Fax+1 (203) 567-1510
- Websitehttps://www.caratherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bio Essence Corp | 593.21k | -1.02m | 9.88m | 12.00 | -- | -- | -- | 16.66 | -0.0278 | -0.0156 | 0.0158 | -0.0458 | 0.3305 | -- | 21.20 | -- | -57.09 | -46.10 | -- | -- | 25.05 | 33.89 | -172.74 | -111.21 | -- | -59.99 | 7.03 | -- | -11.27 | -10.94 | -52.03 | -- | -48.19 | -- |
| Immunoprecise Antibodies Ltd | 17.25m | -19.76m | 10.05m | 102.00 | -- | 0.4045 | -- | 0.5825 | -0.7468 | -0.7468 | 0.6593 | 0.8614 | 0.3546 | 6.12 | 6.16 | -- | -40.63 | -26.70 | -46.68 | -30.31 | 48.21 | 56.13 | -114.58 | -85.72 | 0.8189 | -134.72 | 0.3289 | -- | 18.65 | 17.54 | -2.32 | -- | 16.71 | -- |
| Talphera Inc | 281.00k | -15.64m | 11.88m | 15.00 | -- | 1.23 | -- | 42.28 | -0.6786 | -0.6792 | 0.0118 | 0.5662 | 0.0127 | -- | -- | 18,733.33 | -70.64 | -22.60 | -82.44 | -28.55 | -- | -- | -5,565.48 | -714.87 | -- | -- | 0.00 | -- | -- | -21.26 | -119.16 | -- | -34.33 | -- |
| Gelteq Ltd | 0.00 | -1.54m | 14.82m | -- | -- | 1.05 | -- | -- | -0.1611 | -0.1611 | 0.00 | 1.50 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.38 | -32.41 | 0.0605 | -- | -- | -- | -72.77 | -- | -- | -- |
| Cumberland Pharmaceuticals, Inc. | 36.79m | -10.87m | 15.17m | 91.00 | -- | 0.6107 | -- | 0.4123 | -0.7692 | -0.7692 | 2.61 | 1.77 | 0.4472 | 0.9316 | 3.07 | 404,235.70 | -13.18 | -7.03 | -20.32 | -9.52 | 83.31 | 79.95 | -29.48 | -17.64 | 0.9884 | -29.44 | 0.3967 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Bright Green Corp | 0.00 | -9.03m | 15.33m | 5.00 | -- | 1.71 | -- | -- | -0.0485 | -0.0485 | 0.00 | 0.0467 | 0.00 | -- | -- | 0.00 | -44.63 | -- | -73.32 | -- | -- | -- | -- | -- | -- | -13,031.30 | 0.0828 | -- | -- | -- | 52.54 | -- | -- | -- |
| TherapeuticsMD Inc | 1.60m | -3.97m | 15.34m | 1.00 | -- | 0.5661 | -- | 9.61 | -0.3499 | -0.291 | 0.1399 | 2.35 | 0.0355 | -- | 0.4944 | 1,596,000.00 | -8.81 | -53.35 | -11.41 | -111.61 | 31.45 | 86.67 | -248.56 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| Cara Therapeutics Inc | 8.69m | -95.53m | 17.01m | 55.00 | -- | 24.05 | -- | 1.96 | -1.75 | -1.75 | 0.1589 | 0.0129 | 0.1042 | 0.6312 | 4.59 | 157,927.30 | -114.63 | -35.76 | -142.84 | -40.82 | 56.44 | -- | -1,099.76 | -162.10 | 4.71 | -- | 0.00 | -- | -49.92 | 9.26 | -38.65 | -- | 100.66 | -- |
| Marinus Pharmaceuticals Inc | 31.47m | -140.49m | 17.75m | 165.00 | -- | -- | -- | 0.5642 | -2.47 | -2.47 | 0.5524 | -1.21 | 0.238 | 0.6542 | 7.75 | 190,703.00 | -106.26 | -49.64 | -140.93 | -57.76 | 90.17 | -- | -446.49 | -518.96 | 1.47 | -10.06 | -- | -- | 21.63 | -- | -613.59 | -- | 7.47 | -- |
| DH Enchantment Inc | 100.00 | -173.19k | 19.54m | 1.00 | -- | -- | -- | 195,396.80 | -0.0002 | -0.0002 | 0.00 | -0.0012 | 0.0438 | 0.1493 | -- | 100.00 | -7,579.43 | -- | -- | -- | 0.00 | -- | -173,190.00 | -- | 0.0029 | -14.85 | -- | -- | -95.43 | -- | 59.53 | -- | -- | -- |
| Cyclo Therapeutics Inc | 870.72k | -24.80m | 20.06m | 8.00 | -- | -- | -- | 23.04 | -0.9232 | -0.9232 | 0.0322 | -0.4683 | 0.1605 | 0.342 | 3.54 | 108,840.00 | -457.10 | -132.22 | -- | -215.17 | 91.24 | 90.37 | -2,848.18 | -1,114.04 | 0.1614 | -- | -- | -- | -21.76 | 1.25 | -29.81 | -- | -3.95 | -- |
| China Health Industries Holdings, Inc. | 95.95k | -1.36m | 21.30m | 32.00 | -- | -- | -- | 221.99 | -0.0208 | -0.0208 | 0.0015 | -0.0366 | 0.0037 | 0.5035 | 20.57 | 2,998.44 | -5.18 | 3.04 | -6.89 | 3.66 | -5.34 | 69.55 | -1,419.49 | 28.61 | 0.0377 | -- | 1.76 | -- | 41,225.93 | -55.72 | -15.49 | -- | -- | -- |
| Nexgel Inc | 6.73m | -3.53m | 22.13m | 19.00 | -- | 4.74 | -- | 3.29 | -0.5815 | -0.5815 | 1.10 | 0.6902 | 0.6558 | 3.21 | 6.56 | 354,105.30 | -37.28 | -44.61 | -51.10 | -56.19 | 31.61 | 5.02 | -56.85 | -180.98 | 0.9291 | -- | 0.2235 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| BioXcel Therapeutics Inc | 2.28m | -71.00m | 23.25m | 74.00 | -- | -- | -- | 10.21 | -2.15 | -2.15 | 0.0637 | -2.02 | 0.0305 | 1.14 | 6.17 | 30,756.76 | -95.08 | -74.57 | -168.28 | -84.06 | 10.98 | -- | -3,119.33 | -32,300.74 | 1.81 | -6.54 | 5.55 | -- | 268.00 | -- | -8.02 | -- | -43.26 | -- |
| Polypid Ltd | 0.00 | -26.86m | 23.34m | 59.00 | -- | 10.81 | -- | -- | -7.48 | -7.48 | 0.00 | 0.3172 | 0.00 | -- | -- | 0.00 | -132.55 | -76.92 | -222.42 | -89.61 | -- | -- | -- | -- | -- | -25.48 | 0.7813 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
Data as of Nov 22 2024. Currency figures normalised to Cara Therapeutics Inc's reporting currency: US Dollar USD
19.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.23m | 4.07% |
| Chescapmanager LLCas of 30 Sep 2024 | 1.70m | 3.10% |
| Farallon Capital Management LLCas of 30 Sep 2024 | 1.56m | 2.84% |
| Disciplined Growth Investors, Inc.as of 30 Sep 2024 | 1.11m | 2.03% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 1.11m | 2.02% |
| Two Sigma Advisers LPas of 30 Sep 2024 | 866.30k | 1.58% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 717.87k | 1.31% |
| Millennium Management LLCas of 30 Sep 2024 | 587.91k | 1.07% |
| BNP Paribas Financial Marketsas of 30 Sep 2024 | 582.54k | 1.06% |
| Geode Capital Management LLCas of 30 Sep 2024 | 452.25k | 0.83% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
